Compounded GLP-1 RA drugs: Getting to know about pharmacy compounding
APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.
Compounded GLP-1 RA drugs: Advice to physicians and other prescribers
Compounded GLP-1 RA drugs: What about prices? Are compounded drugs cheaper or more expensive than manufacturers’ versions?
Biden prostate cancer diagnosis: A physician expert offers his first impressions
The former president likely will have drug therapy to lower his testosterone levels, but there are other treatment options.
Compounded GLP-1 RA drugs: Can pharmacists make drugs that are essentially a copy of another drug? Part 2
Biden prostate cancer diagnosis: The newest developments for doctors
Daniel Isaac, DO, MS, an oncologist/hematologist, discusses the publicly disclosed diagnosis of prostate cancer in former President Joe Biden.
Biden prostate cancer diagnosis: The importance of primary care and cancer detection
Biden prostate cancer diagnosis: Surgerical options, and discovering the disease
Biden prostate cancer diagnosis: Treatment options
Biden prostate cancer diagnosis: What we know so far
Compounded GLP-1 RA drugs: GLP-1 RA drugs are no longer in shortage, but compounding customized versions of them may continue, part 1
Compounded GLP-1 RA drugs: A continuing discussion about GLP-1 RA drugs, the perfect storm of demand and shortages, part 2
Compounded GLP-1 RA drugs: Are GLP-1 RA drugs the biggest phenomenon in American health care? Part 1
Compounded GLP-1 RA drugs: Criteria for compounding medicines to fill gaps that drugmakers can’t fill
Compounded GLP-1 RA drugs: An introduction to the Alliance for Pharmacy Compounding
Succeeding in value-based payment: A conversation with Joshua M. Liao, MD
Joshua M. Liao, MD, spoke with Medical Economics following the ACP Internal Medicine Meeting last month about succeeding in value-based payment models.
Why vaccine skepticism is on the rise
Expert physicians discuss the urgent need to rebuild trust in vaccines amid rising skepticism and misinformation during the Trump administration, emphasizing the role of physicians in public health.
Succeeding in value-based payment: Choosing the right model
Joshua M. Liao, MD, outlines three critical factors primary care physicians should consider when deciding between value-based care models.
Succeeding in value-based payment: Aligning incentives for the whole team
Joshua M. Liao, MD, explains how practices can effectively include non-clinical staff in performance incentives.
Succeeding in value-based payment: Beyond face-to-face visits
Joshua M. Liao discusses how primary care practices can adapt to models that reward care delivered outside traditional office visits.
Succeeding in value-based payment: Keeping patients engaged
Joshua M. Liao, MD, offers advice for practices trying to keep patients engaged and connected in a fragmented care environment.
Succeeding in value-based payment: How can small practices navigate patient attribution
Joshua M. Liao, MD, discusses the importance of patient attribution in value-based payment models — and how small practices can get it right.
AI-powered diagnostics: What will the technology look like in 5-10 years?
AI tools are becoming more prevalent in back office operations, but they are also making inroads on the diagnostic side.
AI_powered diagnostics: How will we pay for all these technology advances?
AI-powered diagnostics: How do we ensure rural patients have access to high-tech tools?
AI-powered diagnostics: Which specialties will be impacted the most?
AI-powered diagnostics: Can these tools help alleviate physician burnout?
AI-powered diagnostics: Will patients trust the technology?
AI-powered diagnostics: Why developers need to maintain doctor trust
AI-powered diagnostics: The regulatory hurdles that need to be overcome